← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Tsrl, Inc.
Ann Arbor, MI
$39,602,411
Total funding
32
Grants
Funding over time
peak $3.3M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$39,602,411 · 32
By mechanism
R44$25,473,577 · 8
R43$6,538,937 · 18
U01$5,315,073 · 1
R41$1,153,738 · 2
R21$625,593 · 1
U44$292,746 · 1
Investigators at Tsrl, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Oral Antiviral Prodrugs for Biodefense Initiative$1,114,210
U01 · FY2009 · AI
Microneedle delivery of Trospium Chloride optimized for improved tolerance and patient outcomes in overactive bladder disease$1,097,498
R44 · FY2025 · DK
Oral Antiviral Prodrugs for Biodefense Initiative$1,086,216
U01 · FY2008 · AI
Oral Antiviral Prodrugs for Biodefense Initiative$1,079,540
U01 · FY2007 · AI
Oral Antiviral Prodrugs for Biodefense Initiative$1,061,113
U01 · FY2005 · AI
Improving Absorption and Targeting of Antiviral Drugs$1,000,000
R44 · FY2009 · AI
Prodrugs of Neuraminidase Inhibitors for Increased Oral Bioavailability$1,000,000
R44 · FY2013 · AI
Development of methionyl-tRNA synthetase inhibitors for Gram positive bacterial infections$1,000,000
R44 · FY2017 · AI
Improving Absorption and Targeting of Antiviral Drugs$1,000,000
R44 · FY2007 · AI
Improving Absorption and Targeting of Antiviral Drugs$1,000,000
R44 · FY2008 · AI
Novel, Self-Applied MicroArray Patch (MAP) of Zanamivir for Treatment of the Flu$999,975
R44 · FY2025 · AI
Microneedle Delivery of Zanamivir for the Treatment of Influenza Infections$999,862
R44 · FY2022 · AI
Development of MRS-2541, a methionyl-tRNA synthetase inhibitor, for Gram positive bacterial infections.$999,765
R44 · FY2025 · AI
Novel, Self-Applied MicroArray Patch (MAP) of Zanamivir for Treatment of the Flu$999,746
R44 · FY2024 · AI
Broad Spectrum Antiviral Nucleoside Phosphonate Analogs$999,700
R44 · FY2017 · AI
Microneedle Delivery of Zanamivir for the Treatment of Influenza Infections$999,604
R44 · FY2023 · AI
Microneedle Delivery of Zanamivir for the Treatment of Influenza Infections$998,663
R44 · FY2024 · AI
Microneedle Delivery of Zanamivir for Treatment of Influenza$998,654
R44 · FY2019 · AI
Development of MRS-2541, a methionyl-tRNA synthetase inhibitor, for Gram positive bacterial infections.$998,521
R44 · FY2023 · AI
Broad Spectrum Antiviral Nucleoside Phosphonate Analogs$997,904
R44 · FY2015 · AI